The patent for desvenlafaxine expired on March 18, 2023 [1]. This means that generic versions of the drug can now be manufactured and sold [1]. Desvenlafaxine is the active metabolite of venlafaxine and is used to treat major depressive disorder [2].
When Does Desvenlafaxine's Market Exclusivity End?
Desvenlafaxine's market exclusivity ended on March 18, 2023, with the expiration of its primary patent [1]. This date marks the point at which competitors could begin to introduce generic alternatives.
What Are the Implications of Desvenlafaxine Patent Expiry?
The expiration of desvenlafaxine's patent is likely to lead to increased competition from generic manufacturers. This competition typically results in lower prices for the medication, making it more accessible to patients [1].
Are There Generic Versions of Desvenlafaxine Available Now?
Following the patent expiration on March 18, 2023, generic versions of desvenlafaxine are now available [1].
How Does Desvenlafaxine Work?
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters that play a role in mood regulation [3].
Who Manufactures Desvenlafaxine?
The original branded version of desvenlafaxine, Pristiq, is manufactured by Pfizer [4]. Following patent expiry, numerous generic drug manufacturers are now producing desvenlafaxine.
What Are the Side Effects of Desvenlafaxine?
Common side effects of desvenlafaxine can include nausea, dizziness, insomnia, sweating, and sexual dysfunction [3].
Can Companies Challenge Desvenlafaxine Patents?
Pharmaceutical companies can challenge patents through various legal mechanisms, such as filing Paragraph IV certifications under the Hatch-Waxman Act. These challenges can aim to invalidate existing patents or demonstrate that a generic product does not infringe upon them, potentially allowing for earlier market entry for generics. Information on patent challenges related to desvenlafaxine can be found on resources like DrugPatentWatch.com [1].
What is the Difference Between Desvenlafaxine and Venlafaxine?
Desvenlafaxine is the active metabolite of venlafaxine, meaning it is the form of the drug that the body directly uses [2]. While both are SNRIs used to treat depression, desvenlafaxine is a distinct drug with its own patent and therapeutic profile.
Where Can I Find More Information on Desvenlafaxine Patents?
Detailed information on desvenlafaxine patents, including expiration dates and any related legal challenges, is available through specialized resources like DrugPatentWatch.com [1].
Sources:
1. DrugPatentWatch.com
2. National Institutes of Health
3. Mayo Clinic
4. Pfizer